ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first quarter of 2024. "This quarter we demonstrated ...

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effectsPublished data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533 as monotherapy and in combination with azacitidine/venetoclaxOngoing Phase 1/ ...

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States. "We are excited to launch Life Science Cares Switzerland (LSCS) today, in time, to engage with the local community at the upcoming Swiss Biotech Day in Basel," said Nadine Zahnd, Ma ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS conso ...

Molecular Partners AG (NASDAQ:MOLN) Q4 2023 Earnings Conference Call March 15, 2024 8:00 AM ET Company Participants Seth Lewis - SVP, IR Patrick Amstutz - CEO Robert Hendriks - SVP, Finance Philippe Legenne - Acting Chief Medical Officer Anne Goubier - SVP, Research & Early Development Daniel Steiner - SVP Research & Technology Conference Call Participants Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Kathleen Silverman - Leerink Joris Zimmermann - Octavian Operator Good day, and welcome to the M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

CD123 MP0533 Induces Specific Killing of AML Cells 10 -2 10 -1 10 0 10 1 10 2 10 3 10 0 25 50 75 100 % cell killing 4 10 5 Concentration [pM] CD33+CD70+ CD123+ CD123 CD70 CD33 CD33 CD123 CD70 Patient population AML or MDS/AML R/R to HMA, induction CT or allogenic HSCT N=20–45 patients 21 Effective radioligands deliver a sufficiently large dose of radioactivity to the tumor for cell killing, while sparing healthy tissues Therapeutic Radioisotope Linker Ligand Therapeutic radioisotope: DNA damage to kill tumo ...

Patrick Amstutz Patrick Amstutz Molecular Partners AG (NASDAQ:MOLN) Q2 2023 Earnings Conference Call August 25, 2023 8:00 AM ET Seth Lewis - SVP, IR Patrick Amstutz - CEO Robert Hendriks - SVP, Finance Daina Graybosch - SVB Leerink LLC Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Good day, and welcome to the Molecular Partners First Half 2023 Results Conference Call. [Operator Instructions] Thank you. Seth Lewis, Senior Vice President of Investor Relations you may begin your conference. Thanks R ...

Exhibit 99.1 Condensed consolidated interim financial statements (unaudited) | | | March 31, | December | | --- | --- | --- | --- | | Condensed consolidated interim statement of financial position as of | | 2023 | 31, 2022 | | in CHF thousands | Note | | | | Assets | | | | | Property, plant and equipment | | 6,768 | 7,235 | | Intangible assets | | 287 | 271 | | Total non-current assets | | 7,055 | 7,506 | | Short-term time deposits | | 158,442 | 161,198 | | Other current assets | | 3,363 | 4,589 | | Trade a ...

Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Conference Call March 10, 2023 8:00 AM ET Company Participants Seth Lewis - Senior Vice President, Investor Relations Patrick Amstutz - Chief Executive Officer Robert Hendriks - Senior Vice President, Finance Conference Call Participants Joe Walton - Credit Suisse Georgi Yordanov - TD Cowen Daina Graybosch - SVB Securities Operator Good day and welcome to the Molecular Partners Publication of Full Year Results 2022 Conference Call. [Operator Instructions] ...